Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs 744

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 744 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Pipeline programs

Page 1 of 16

  1. 1378-0041

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  2. 1404-0038

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  3. 1404-0040

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  4. 1404-0041

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  5. 1404-0056

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  6. 14V-MC-JAJK

    Eli Lilly Co.

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  7. 2-mg Intravitreous Aflibercept Injection

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  8. 2.0 mg intravitreal aflibercept

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  9. 20220196

    Amgen

    Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweight

    phase 3 small molecule active

    1 trial

  10. 20230225

    Amgen

    "Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"

    phase 3 small molecule active

    1 trial

  11. 20230227

    Amgen

    Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    phase 3 small molecule active

    1 trial

  12. 21177

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  13. 8 mg aflibercept (BAY 86-5321) (High Dose)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  14. ANDA219975 + ANDA220011

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  15. APHP180591

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  16. Aflibercept

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  17. Aleglitazar

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    2 trials

  18. Alirocumab

    Regeneron UK Limited

    Type2 Diabetes

    phase 3 small molecule completed

    1 trial

  19. Alogliptin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    5 trials

  20. Alogliptin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    9 trials

  21. Alogliptin Benzoate

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  22. Alogliptin and glimepiride

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  23. Alogliptin and glyburide

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  24. Alogliptin and insulin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  25. Alogliptin and metformin

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  26. Alogliptin and metformin

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  27. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  28. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  29. Alogliptin and voglibose

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  30. Aramchol free acid

    Galmed Pharmaceuticals

    Nonalcoholic Steatohepatitis (NASH)

    phase 3 small molecule on hold

    1 trial

  31. BAT5906 injection

    Bio-Thera Solutions

    Diabetic Macular Edema (DME)

    phase 3 small molecule active

    1 trial

  32. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  33. BT-001

    CATALYST PHARMACEUTICALS, INC.

    Type2 Diabetes

    phase 3 other terminated

    1 trial

  34. Betamethasone Microsphere (DE-102） Low Dose

    Santen Oy

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  35. Bevacizumab

    Hospital Authority, Hong Kong

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  36. Biological/Vaccine

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 3 mab active

    1 trial

  37. Botulinum toxin type A

    Hospital Authority, Hong Kong

    Obesity

    phase 3 small molecule active

    1 trial

  38. CKD-501 0.5mg

    Hong Kong Baptist University

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  39. CSII (Insulin Pump) plus DAFNE

    United Therapeutics Europe Ltd

    Type 1 Diabetes

    phase 3 other completed

    1 trial

  40. CT-L03-301

    Celltrion Healthcare Australia Pty Ltd

    Type 2 diabetes mellitus (T2DM)

    phase 3 small molecule active

    1 trial

  41. Cadisegliatin 800 mg QD

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 3 small molecule active

    1 trial

  42. Canagliflozin

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  43. Capsaicin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetic Polyneuropathy

    phase 3 small molecule completed

    1 trial

  44. D20180102

    Pari Pharma GmbH

    Vascular calcification and type 1 diabetes

    phase 3 small molecule active

    1 trial

  45. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  46. Dapagliflozin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    3 trials

  47. Dapagliflozin 10 mg

    AstraZeneca

    Type 2 Diabetes Mellitus

    phase 3 small molecule terminated

    1 trial

  48. Dapagliflozin 10 mg

    AstraZeneca

    Diabetes Mellitus, Non-Insulin-Dependent

    phase 3 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

744 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.